CSL - INF 0506

中超-INF 0506

• 批准号: 7605663
• 负责人: Kathryn Margaret Edwards
• 金额: $ 12.18万
• 依托单位: VANDERBILT UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-12-01 至 2007-09-16
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605663
• 关键词: Adult; Clinical Trials; Computer Retrieval of Information on Scientific Projects Database; Food; Funding; Grant; Institution; Outcome; Pharmaceutical Preparations; Research; Research Personnel; Resources; Source; Thimerosal; United States National Institutes of Health; immunogenicity; influenza virus vaccine; placebo controlled study

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This clinical trial is being conducted to satisfy the Food and Drug Adminisration (FDA) requirements for accelerated approval of the CSL Influenza Vaccine in the US. In order to obtain an indication for healthy adults, CSL must conduct a placebo-controlled study to meet defined immunogenicity outcomes for all 3 influenza vaccine strains. (Thimerosal-free)

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 对于中心来说，它不一定是研究者的机构。 正在进行这项临床试验，以满足美国食品药品监督管理局 (FDA) 加速批准 CSL 流感疫苗的要求。 为了获得健康成人的适应症，CSL 必须进行安慰剂对照研究，以满足所有 3 种流感疫苗株的既定免疫原性结果。 （不含硫柳汞）